Vaccine study for certain melanoma patients with specific blood markers
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a modified vaccine to help the immune system recognize melanoma. It is mainly for people with melanoma at higher risk or certain stages, and who have specific inherited tissue markers on blood testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your melanoma must be stage IIb/IIc, III, IV after surgery, or non-surgical low-volume metastatic melanoma
- Your blood/type testing must show at least one of the listed HLA markers (HLA-A2, A24, A33, B35, B49, or CW04/12)
- If your tumor has the BRAF V600E mutation, you must have already had targeted treatment; many people also need prior chemo and immunotherapy
- You should be well enough to do normal activities with effort (Karnofsky score over 80)
- You must not have major breathing or heart problems that are currently active
- You must avoid recent chemotherapy or large radiation (within 28 days) and must not have active serious infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab (Keytruda) in people with advanced melanoma that cannot be removed by surgery. The goal is to see if this combination helps the immune system fight the cancer better.
This trial is looking at a protein called CD160 on immune cells (NK cells) in melanoma patients. The goal is to understand if this protein can be a target for new treatments. By studying your blood and tumor samples, researchers hope to find better ways to treat advanced melanoma.
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
Hear when a new Malignant Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.